Cormorant Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Cormorant Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.8M	Sell	225,000 -25,000	-10%	-$1.75M	0.79%	30
2025 Q4	$20.5M	Sell	250,000 -50,000	-17%	-$3.73M	0.95%	23
2025 Q3	$17.8M	Hold	300,000	–	–	1.23%	21
2025 Q2	$12.2M	Sell	300,000 -100,000	-25%	-$4.5M	0.91%	24
2025 Q1	$20.5M	Sell	400,000 -100,000	-20%	-$4.94M	1.55%	19
2024 Q4	$27.7M	Hold	500,000	–	–	1.52%	20
2024 Q3	$16.4M	Hold	500,000	–	–	0.87%	33
2024 Q2	$13.6M	Sell	500,000 -1,639,102	-77%	-$55.1M	0.79%	33
2024 Q1	$77.8M	Sell	2,139,102 -82,320	-4%	-$2.42M	3.41%	8
2023 Q4	$45M	Sell	2,221,422 -400,000	-15%	-$6.68M	2.15%	12
2023 Q3	$46.6M	Buy	2,621,422 +1,200,000	+84%	+$21.2M	2.72%	11
2023 Q2	$25.7M	Hold	1,421,422	–	–	1.44%	20
2023 Q1	$17.9M	Sell	1,421,422 -315,000	-18%	-$4.61M	1.18%	23
2022 Q4	$25.5M	Sell	1,736,422 -235,000	-12%	-$3.89M	1.7%	19
2022 Q3	$33.8M	Buy	1,971,422 +96,422	+5%	+$1.53M	2.36%	12
2022 Q2	$27.4M	Buy	1,875,000 +499,018	+36%	+$7.49M	2.07%	16
2022 Q1	$23.1M	Sell	1,375,982 -27,349	-2%	-$508K	1.78%	15
2021 Q4	$31.6M	Sell	1,403,331 -41,500	-3%	-$1.08M	1.88%	16
2021 Q3	$31.1M	Sell	1,444,831 -69,438	-5%	-$1.72M	1.27%	24
2021 Q2	$43.9M	Sell	1,514,269 -200,000	-12%	-$6.25M	1.49%	22
2021 Q1	$55.3M	Hold	1,714,269	–	–	1.23%	20
2020 Q4	$70M	Buy	+1,714,269	New	+$48.8M	1.67%	22

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cormorant Asset Management's TARS Position: Q1 2026 in Review

Cormorant Asset Management reduced its Tarsus Pharmaceuticals (TARS) stake by 10% in Q1 2026, selling an estimated $1.75M and leaving 225,000 shares worth $15.8M. The position accounts for 0.79% of the portfolio, ranked #30.

Cormorant Asset Management first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $77.8M in Q1 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Cormorant Asset Management held 225,000 shares of Tarsus Pharmaceuticals worth $15.8M as of Q1 2026.
Cormorant Asset Management sold 25,000 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $1.75M.
Tarsus Pharmaceuticals made up 0.79% of Cormorant Asset Management's portfolio in Q1 2026, its #30 holding.
Cormorant Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Cormorant Asset Management's Tarsus Pharmaceuticals position peaked at $77.8M in Q1 2024.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.